Novavax stock: Sanofi trial triggers $125 million milestone

Published on 10/30/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novavax stock faces a new partnership catalyst after Sanofi dosed the fifth patient in a Phase 3 trial. Results are due November 5.

Sanofi partnership advances

Sanofi has started a European Phase 3 trial combining Nuvaxovid with its high-dose flu vaccine in older adults.
Novavax remains eligible for further milestones and royalties as the partnership moves toward manufacturing and possible U.S. commercialization.

NVAX, US6700024010, Illustration mit AI erstellt.

Novavax said on October 29 that it had earned a $125 million milestone payment after Sanofi dosed the fifth patient in a European Phase 3 trial for an influenza-COVID-19 combination vaccine. The announcement came from the company and concerns the use of Novavax's Nuvaxovid as the COVID-19 component.

Trial opens further revenue paths

The study is assessing safety and immune response in adults aged 60 and older. It combines Nuvaxovid with Sanofi's marketed Efluelda/Fluzone High-Dose influenza vaccine.

Novavax said its collaboration with Sanofi has generated more than $1 billion in revenue to date. The agreement also provides for royalties on Nuvaxovid sales, combination products using Nuvaxovid and future vaccines developed with Novavax's Matrix-M adjuvant.

Further potential payments include $75 million after the planned completion of manufacturing technology transfer, which Novavax expects in mid-2027. A U.S. launch of an influenza-COVID-19 combination vaccine could trigger another $225 million after Sanofi completes the required clinical and regulatory steps.

Those future amounts depend on manufacturing, trial and regulatory execution. Novavax cautioned that additional clinical studies may be needed for U.S. filings and that U.S. requirements may differ from those in other markets.

Quarterly results next week

Novavax plans to release its third-quarter 2026 results before the U.S. market opens on Thursday, November 5. Management is scheduled to discuss the figures and operating developments during a webcast and conference call at 8:30 a.m. Eastern Time.

Novavax stock traded at 9.01 euros on Lang & Schwarz at 18:33 CET on Friday, October 30, 2026. The real-time quote of Novavax stock is available separately.